Debate over naming of biosimilars intensifies

摘要

Drag regulators have noticed a proliferating problem. Around the world, various regional regulators are applying different naming conventions for biosimilars. So several regulators asked the World Health Organization (WHO) -which has responsibility for giving drugs their generic names under the International Non-proprietary Name (INN) programme - to devise a global nomenclature for biosimilars.